E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers K > Headlines for Kindred Biosciences, Inc. > News item
Published on 3/31/2014 in the Prospect News PIPE Daily.

Kindred Biosciences intends to price $50 million public sale of stock

Leerink Partners, BMO Capital and Guggenheim are the joint bookrunners

By Devika Patel

Knoxville, Tenn., March 31 - Kindred Biosciences, Inc. said it will raise about $50 million in a public offering of stock.

Leerink Partners LLC is the lead bookrunner, and BMO Capital Markets Corp. and Guggenheim Securities, LLC are the joint bookrunning managers.

The biopharmaceutical company is based in San Francisco.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.